Phenotypic and genetic diversity of the traditional Lister smallpox vaccine

Vaccine

Volumn 27, Issue 5, 2009, Pages 708-717

  Garcel, Aude ^a   Perino, Julien ^a   Crance, Jean Marc ^a   Drillien, Robert ^b,c   Garin, Daniel ^a,d   Favier, Anne Laure ^a  

^a Centre de Recherches   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d 2ème Centre Médical des Armées   (France)

Author keywords

Heterogeneity; Smallpox vaccine; Vaccinia virus

Indexed keywords

NEUTRALIZING ANTIBODY; SMALLPOX VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BRAIN; CELL STRAIN BHK; CONTROLLED STUDY; COWPOX VIRUS; FEMALE; GENETIC VARIABILITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SMALLPOX; SMALLPOX VIRUS; VACCINE PRODUCTION; VERO CELL; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; BODY WEIGHT; BRAIN; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; FEMALE; GENETIC VARIATION; HUMANS; LUNG; MICE; MICE, INBRED BALB C; PHYLOGENY; PLAQUE ASSAY; SEQUENCE HOMOLOGY; SMALLPOX; SMALLPOX VACCINE; SURVIVAL ANALYSIS; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 58149492526     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.063     Document Type: Article

References (43)

1. Fenner F. Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Res Virol 140 5 (1989) 465-466 discussion 87-91
2. Levy-Bruhl D., and Guerin N. The use of smallpox virus as a biological weapon: the vaccination situation in France. Euro Surveill 6 11 (2001) 171-178
3. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 22 (1999) 2127-2137
4. Alibek K. Smallpox: a disease and a weapon. Int J Infect Dis 8 Suppl. 2 (2004) 3-8
5. Bricaire F., Combadiere B., Rouleau E., Bossi P., Garin D., Lebrun-Vignes B., et al. Evaluation of residual immune response against human pox virus before and after revaccination in healthy volunteers. Bull Acad Natl Med 190 4-5 (2006) 1035-1046 discussion 46-9
6. Rosenthal S.R., Merchlinsky M., Kleppinger C., and Goldenthal K.L. Developing new smallpox vaccines. Emerg Infect Dis 7 6 (2001) 920-926
7. Garin D., Crance J.M., Fuchs F., Autran B., and Drillien R. Actualites sur la vaccination antivariolique. Update on smallpox vaccines. Médecine et maladies infectieuses 34 (2004) 20-27
8. Greenberg M. Complications of vaccination against smallpox. Am J Dis Child 76 (1948) 492-502
9. Ferry B.J. Adverse reactions after smallpox vaccination. Med J Aust 6 2 (1977) 180-183
10. Cono J., Casey C.G., and Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 52 RR-4 (2003) 1-28
11. Osborne J.D., Lin S., Zhu L., and Kibbe W.A. Mining biomedical data using MetaMap Transfer (MMtx) and the Unified Medical Language System (UMLS). Methods Mol Biol 408 (2007) 153-169
12. Li G., Chen N., Feng Z., Buller R.M., Osborne J., Harms T., et al. Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication. Virol J 3 (2006) 88
13. Weltzin R., Liu J., Pugachev K.V., Myers G.A., Coughlin B., Blum P.S., et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9 9 (2003) 1125-1130
14. Scaramozzino N., Ferrier-Rembert A., Favier A.L., Rothlisberger C., Richard S., Crance J.M., et al. Real-time PCR to identify variola virus or other human pathogenic orthopox viruses. Clin Chem 53 4 (2007) 606-613
15. Ferrier-Rembert A., Drillien R., Tournier J.N., Garin D., and Crance J.M. Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines. Vaccine 25 25 (2007) 4809-4817
16. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., and Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 181 1 (2000) 10-19
17. Martinez M.J., Bray M.P., and Huggins J.W. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch Pathol Lab Med 124 3 (2000) 362-377
18. Leparc-Goffart I., Poirier B., Garin D., Tissier M.H., Fuchs F., and Crance J.M. Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J Clin Virol 32 1 (2005) 47-52
19. Lee H.J., Essani K., and Smith G.L. The genome sequence of Yaba-like disease virus, a yatapoxvirus. Virology 281 2 (2001) 170-192
20. Kumar S., Tamura K., and Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5 2 (2004) 150-163
21. Garcel A., Crance J.M., Drillien R., Garin D., and Favier A.L. Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses. J Gen Virol 88 Pt 7 (2007) 1906-1916
22. Goebel S.J., Johnson G.P., Perkus M.E., Davis S.W., Winslow J.P., and Paoletti E. The complete DNA sequence of vaccinia virus. Virology 179 1 (1990) 247-66, 517-63
23. Morikawa S., Sakiyama T., Hasegawa H., Saijo M., Maeda A., Kurane I., et al. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol 79 18 (2005) 11873-11891
24. Li G., Chen N., Roper R.L., Feng Z., Hunter A., Danila M., et al. Complete coding sequences of the rabbitpox virus genome. J Gen Virol 86 Pt 11 (2005) 2969-2977
25. Turner G.S. Respiratory infection of mice with vaccinia virus. J Gen Virol 1 3 (1967) 399-402
26. Lin C.L., Chung C.S., Heine H.G., and Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 74 7 (2000) 3353-3365
27. Ludvikova V., Kutinova L., Simonova V., and Otavova M. Evaluation of various virulence tests with low virulence vaccinia virus in mice. Biologicals 22 2 (1994) 187-190
28. Ginsberg A.H., and Johnson K.P. Vaccinia virus meningitis in mice after intracerebral inoculation. Infect Immun 13 4 (1976) 1221-1227
29. Li Z., Rubin S.A., Taffs R.E., Merchlinsky M., Ye Z., and Carbone K.M. Mouse neurotoxicity test for vaccinia-based smallpox vaccines. Vaccine 22 11-12 (2004) 1486-1493
30. Grosenbach D.W., Hansen S.G., and Hruby D.E. Identification and analysis of vaccinia virus palmitylproteins. Virology 275 1 (2000) 193-206
31. Fonseca F.G., Lanna M.C., Campos M.A., Kitajima E.W., Peres J.N., Golgher R.R., et al. Morphological and molecular characterization of the poxvirus BeAn 58058. Arch Virol 143 6 (1998) 1171-1186
32. Ropp S.L., Jin Q., Knight J.C., Massung R.F., and Esposito J.J. PCR strategy for identification and differentiation of small pox and other orthopoxviruses. J Clin Microbiol 33 8 (1995) 2069-2076
33. Leite J.A., Drumond B.P., Trindade G.S., Lobato Z.I., da Fonseca F.G., dos S.J., et al. Passatempo virus, a vaccinia virus strain, Brazil. Emerg Infect Dis 11 12 (2005) 1935-1938
34. Kutinova L., Ludvikova V., Simonova V., Otavova M., Krystofova J., Hainz P., et al. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine 13 5 (1995) 487-493
35. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8 Suppl. 2 (2004) 31-44
36. Kenner J., Cameron F., Empig C., Jobes D.V., and Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24 47-48 (2006) 7009-7022
37. Phelps A., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of replicating smallpox vaccine strains in a Murine Challenge Model. Vaccine 23 27 (2005) 3500-3507
38. Ferrier-Rembert A.D.R., Meignier B., Garin D., and Crance J.-M. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate. Vaccine 25 49 (2007) 8290-8297
39. Artenstein A.W., Johnson C., Marbury T.C., Morrison D., Blum P.S., Kemp T., et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23 25 (2005) 3301-3309
40. Lee M.S., Roos J.M., McGuigan L.C., Smith K.A., Cormier N., Cohen L.K., et al. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol 66 5 (1992) 2617-2630
41. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 16 (2003) 9458-9463
42. Xu R., Johnson A.J., Liggitt D., and Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 172 10 (2004) 6265-6271
43. Osborne J.D., Da Silva M., Frace A.M., Sammons S.A., Olsen-Rasmussen M., Upton C., et al. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine 25 52 (2007) 8807-8832